



Press release

Giuliani S.p.A acquires majority stake in MIKA Pharma GmbH

Ludwigshafen, Germany / Milano, Italy; March 23, 2010: MIKA Pharma GmbH today announced that Giuliani S.p.A, a Milano, Italy based Pharma company has acquired a majority stake in MIKA Pharma.

Based on its proprietary nanoemulsion drug delivery technology, MIKA Pharma has developed a wide range of topical products including Diclofenac Spray, Ketoprofen Spray, and Heparin Spray. All of these products were successfully developed by MIKA Pharma and are currently registered in 32 countries. MIKA Pharma has granted licensing rights to a variety of partners to commercialise these products. In addition MIKA Pharma is developing a broad clinical pipeline of topical products for the treatment of pain and inflammation.

Bernd Seigfried, CEO of MIKA comments: Giuliani S.p.A is the preferred strategic partner to further develop our international clinical projects. At the same time we already have products in commercial stage, here as well Giuliani S.p.A will help to faster exploit the various market opportunities.

Dr. Germano Giuliani, CEO and President of Giuliani S.p.A adds: MIKA Pharma is a significant addition to our Pharma pipeline, bringing new products and technologies to our company that offer a great opportunity for growth on an international basis.

Mr. Seigfried will stay a shareholder in the company and will continue to serve as CEO of MIKA Pharma. Dr. Germano Giuliani and Dr. Alexander Asam (HBM Partners AG) will join the Board of Directors of MIKA Pharma.

About MIKA Pharma GmbH

MIKA Pharma GmbH was established in 1994 for the development and production of primarily dermal, transdermal, and buccal application systems for pharmaceuticals on the basis of sprayable liposomes, pre-liposomal solutions and proprietary micellar nano-solutions. The overall MIKA Pharma GmbH portfolio contains products and clinical projects in various indication areas such as: sports injuries, rheumatic disorders, pain, superficial thrombophlebitis, cough, fungal infections, various skin disorders.



About Giuliani S.p.A

Giuliani S.p.A., founded in 1889, is a privately owned specialty pharmaceutical company strategically focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn's disease, food intolerances and dermatological disorders. Giuliani's R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

For further information, please contact:

For MIKA Pharma:

Bernd G. Seigfried, CEO MIKA Pharma GmbH,
Tel.: +49 (0) 621 591 87 100; Bernd.Seigfried@mika-pharma.de

MIKA Pharma GmbH
An der Rheinschanze 1
67059 Ludwigshafen, Germany
www.mika-pharma.com

For Giuliani S.p.A

Dr. Germano Giuliani, CEO & President Giuliani S.p.A
Tel.: +39 02 20541 mggiuliani@giulianipharma.com

Giuliani S.p.A.
Via Palagi 2
20129 Milano, Italy
www.giulianipharma.com

Disclaimer:

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law.